After a few hours, a large number of neutrophils and monocytes entered the mouse airway. These immune cells release a large number of inflammatory factors such as IL-6 and in the airway of mice, and IL-1β and monocyte chemotactic factor CCL2 aso appear in the lung. Interestingly, however, these pro-inflammatory effects do not occur in soluble Gal10 mutants.

Since only Gal10 crystals can trigger these inflammatory reactions, if these crystals can be dissolved, can it alleviate the inflammation of chronic sinusitis, asthma and other diseases? The researchers developed an antibody 1D11 that can dissolve Gal10 crystals. 1D11 can dissolve Gal10 crystals within 2 hours, and can also dissolve CLCs crystals in mucus of patients with chronic sinusitis. In a mouse model of dust mite-induced asthma, 1D11-CLCs lysis treatment completely neutralized the pro-inflammatory effects of CLCs. Therefore, the use of these antibodies may be a very effective method to reduce excessive inflammation and mucus accumulation in the lungs of asthmatic patients. Since there is currently no drug for airway mucus accumulation, this research may change the way the disease is treated.